Navigation Links
Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
Date:1/29/2008

TORONTO, Jan. 29 /PRNewswire/ - Viventia Biotech Inc., a privately held biopharmaceutical company advancing a portfolio of novel antibody therapeutics focused on cancer, announced today it intends to explore strategic alternatives to further advance and realize value from its pipeline of therapeutic antibodies, its antibody discovery platform and its antibody manufacturing capabilities. The Company will consider potential strategic opportunities including, but not limited to, the sale or merger of the Company with another entity, and has retained HSBC to act as advisors in this process.

The Company also provided an update on the clinical development programs for Proxinium(TM) (Phase 3), Vicinium(TM) (Phase 2) and VB6-845 (Phase 1). Proxinium(TM) is undergoing a global pivotal Phase 3 trial (the 'TARGET' trial) in approximately 300 patients with advanced head and neck cancer. Viventia recently completed an interim efficacy assessment on the study's primary endpoint of median survival. These preliminary results demonstrated a clear survival advantage in the Proxinium(TM) arm.

"We have successfully advanced three antibody programs into clinical trials, and are about twelve months from expected final efficacy data for our pivotal Phase 3 TARGET trial of Proxinium(TM). We believe that our recently performed interim efficacy analysis of survival data from TARGET strongly supports the future prospects for this drug. In addition to our clinical programs, we have generated a broad pipeline from our antibody discovery platform, which has yielded a number of compelling novel targets, including several that have expression profiles consistent with cancer stem cells, an exciting new area of cancer research," said Dr. Nick Glover, President and CEO of Viventia Biotech. "We believe it is important to explore all options to ensure adequate resources are available for the advancement of our products through to commercialization and to further recognize the value
'/>"/>

SOURCE Viventia Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
3. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
4. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
5. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
10. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
11. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015  Derma Sciences, Inc. (Nasdaq: ... on advanced wound care, announces that AMNIOEXCEL® and ... been added to the Premier, Inc. Regenerative Skin ... for the AMNIOEXCEL® and AMNIOMATRIX® product lines, which ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
(Date:12/24/2014)... Earlier this year in a June 24 ... Adult Stem Cell Technology Center, LLC ( ASCTC ) focused ... of adult tissue stem cells. His title “Asymmetric Self-Renewal ... the Future,” embodied the essence of his message to congress ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 The ... as its definition, classification, application and industry overview. ... and product cost structure. Production is separated by ... upstream raw materials, equipment, downstream client survey, marketing ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... , , , ... of hospital-related infections in the U.S. costs up to $11 billion a ... implanted in patients. Until now, efforts to control drug-resistant biofilms on such ... mats developed by collaborators Pat Mather and Dacheng Ren of the Syracuse ...
... ... announced the PX14400 high-speed digitizer, the industry,s most advanced wideband and high dynamic ... when using the programmable gain amplifier in 1 dB steps for maximum gain ... is employed for the cleanest possible signal path to the ADC. 1 GB ...
... /PRNewswire/ - Enerkem, a leading waste-to-biofuels and green chemicals ... by its partners, the City of Edmonton and the ... on their joint advanced energy research facility. The ceremony ... Advanced Education and Technology in Alberta, and the Edmonton ...
Cached Biology Technology:New Antimicrobial Webs Sterilize Medical Implants for 14 Days 2Signatec Unveils PX14400, Its High-Speed PCI-Express Digitizer Capable of Sustained Recordings Over 1.2 GB/s with Xilinx Virtex-5 FPGAs for Embedded Real-Time Processing 2Signatec Unveils PX14400, Its High-Speed PCI-Express Digitizer Capable of Sustained Recordings Over 1.2 GB/s with Xilinx Virtex-5 FPGAs for Embedded Real-Time Processing 3Signatec Unveils PX14400, Its High-Speed PCI-Express Digitizer Capable of Sustained Recordings Over 1.2 GB/s with Xilinx Virtex-5 FPGAs for Embedded Real-Time Processing 4Enerkem Announces Construction Start on Advanced Energy Research Facility in Edmonton, Alberta 2Enerkem Announces Construction Start on Advanced Energy Research Facility in Edmonton, Alberta 3
(Date:1/22/2015)... /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry news, ... website design. "When we launched FindBiometrics 12 years ... O,Neill , founder and CEO of FindBiometrics. "Now it,s maturing ... the key players on a very broad scale.  We are ...
(Date:1/22/2015)... , Jan. 16, 2015  A man-made form of insulin ... other mental capabilities in adults with mild cognitive impairment ... led by researchers at Wake Forest Baptist Medical Center. ... with amnesic mild cognitive impairment (MCI) or mild to ...
(Date:1/22/2015)... 2015 , Europe,s ... The European Patent Office to present a video retrospective of the ... be featured: Christofer Toumazou and Sophie Wilson   ... winners of the Award   Starting on 22 January ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... Researchers at Mount Sinai School of Medicine have just ... of the microdomains of leukocytes or white blood cells. ... cells in which receptors and signaling molecules accumulate during ... to view white blood cell subsets and their forming ...
... health care and medicine, but current technologies only give a ... complete picture of their inherited DNA, or genome, would drop ... the current tune of $10 million or more charged for ... grant award from the National Human Genome Research Institute (NHGRI), ...
... Tech researchers in computer science and biology have used ... algorithms that make it possible to simulate the cell ... have demonstrated that the new mathematical models and numerical ... going on inside living cells. , Biologist John Tyson, ...
Cached Biology News:New imaging technique tracks traffic patterns of white blood cells 2Faster, low cost sequencing technologies needed to drive era of personalized medicine 2Faster, low cost sequencing technologies needed to drive era of personalized medicine 3Virginia Tech's System X supercomputer provides super tool for simulation of cell division 2Virginia Tech's System X supercomputer provides super tool for simulation of cell division 3
... DNA polymerase from Thermus aquaticus expressed in ... 1 tube of 250 units enzyme/tube and ... DNA), is the same enzyme as AmpliTaq ... a proprietary separation process to ensure that ...
... 5 units/µL ,• High specific activity and ... an 'A' overhang ,• Processes ... very high activity in primer extension and ... quality of the enzyme, each lot has ...
... AmpliTaq DNA Polymerase is the most thoroughly ... a testimony to its overall utility and ... it ideal for PCR applications. , ... results. ,, AmpliTaq DNA Polymerase is ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I...
Biology Products: